title: Antiangiogenic effects of zoledronate on cancer neovasculature.
abstract: Angiogenesis, one of the hallmarks of cancer, supplies nutrients to cancerous tissues to facilitate rapid growth. Targeting cancer-associated angiogenesis is an important goal in cancer therapy and there are currently many drugs that affect tumor-associated vasculature. In this article, we will focus on the antiangiogenic effects of zoledronate (ZA), a bisphosphonate drug routinely used in the treatment of cancer-associated bone disease. This article covers the known effects of ZA throughout the clinical process. It also covers the animal models of cancer that have been treated with ZA and evaluated for angiogenes is, concluding with the current clinical data pertaining to angiogenic factors after ZA treatment.
authors: Postgraduate Medical School, Faculty of Health & Medical Sciences, University of Surrey, UK.
authors: Stephen
authors: S
authors: Metcalf
authors: Hardev S
authors: HS
authors: Pandha
authors: Richard
authors: R
authors: Morgan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy; D004164:Diphosphonates / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D000077211:Zoledronic Acid
chemical_list: D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid